Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Monitoring
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Alcohol and drug treatment
Digital technology - benefits and risks
Alcohol — Monitoring
E-health — Monitoring
Infectious diseases — Monitoring
Markets — Monitoring
Monitoring — New trends
Monitoring — Treatment: medical/pharmacological
Opiates — Monitoring
Wednesday, 23 October
10:50
High-risk drug use and health threats in Eastern Europe
Focus on the EU borders
10:50
to
12:20
Central square 3 (C3)
Katri Abel-Ollo
Anne Bergenström
Innovative methods for exploring new drug-related trends
10:50
to
12:20
Insights zone 4 (I4)
João Matias
Stimulants — use, harm and interventions
10:50
to
12:20
Networking zone 4 (N4)
Janusz Sieroslawski
Definition of disorders
10:50
to
12:20
Networking zone 1 (N1)
Viktor Mravčík
12:20
Measuring drug use to monitor trends in different populations - ISSDP poster session 1
12:20
to
13:20
Guided poster tours room
Nicola Singleton
13:20
The challenges of monitoring new drugs
13:20
to
14:50
Insights zone 2 (I2)
Ana Gallegos
16:50
Towards a public health approach
An epidemiological overview of new psychoactive substances use in Europe
16:50
to
18:20
Central square 3 (C3)
Margriet van Laar
Developing tools for monitoring of drug policy and practice from the view point of civil society organisations in Europe
16:50
to
18:20
Insights zone 1 (I1)
Eberhard Schatz
18:30
Innovative approaches for assessing or impacting demand for substances
18:30
to
19:30
Central square 1 (C1)
Anne Line Bretteville-Jensen
Thursday, 24 October
10:50
Methods and approaches to inform drug policy and practice
10:50
to
12:20
Networking zone 4 (N4)
Márya Hynes
Understanding behaviours, risks and harms
10:50
to
12:20
Networking zone 3 (N3)
Xavier Majó
Monitoring trends and developments
10:50
to
12:20
Insights zone 1 (I1)
Larissa Maier
12:20
Making better use of existing data through standardisation, methods and analysis - ISSDP poster session 2
12:20
to
13:20
Guided poster tours room
Rosalie Pacula
13:20
Addicted to work: the use of cognitive enhancers in the workplace and the implications for occupational safety and health
13:20
to
14:50
Futures zone 2 (F2)
William Cockburn
Opioid-related deaths: learning from pharmacology, laboratory-based studies and physical assessments
13:20
to
14:50
Central square 1 (C1)
Sir John Strang
Reducing drug-related deaths
13:20
to
14:50
Central square 2 (C2)
Catherine Comiskey
Treatment adherence
13:20
to
14:50
Insights zone 4 (I4)
Marta Torrens Melich
Using new technology and innovative methods to measure substance use and related harm
13:20
to
14:50
Networking zone 1 (N1)
Peter Reuter
The Reitox network poster session
13:20
to
14:50
Guided poster tours room
Nadine Berndt
15:00
Methodological challenges and comparative analyses in five European countries
Insight into the dynamics of substance use (research) in nightlife settings
15:00
to
16:30
Networking zone 1 (N1)
João Matias
Drug markets
15:00
to
16:30
Insights zone 4 (I4)
Dirk Korf
Opioid-related deaths and other harms: current and emerging lessons - SSA poster session
15:00
to
16:30
Guided poster tours room
Sarah Welch
16:50
Emerging drug trends in North Africa and Middle East
Focus on the EU borders
16:50
to
18:20
Insights zone 2 (I2)
Ioanna Yiasemi
Thomas Néfau
Factors influencing recovery
16:50
to
18:20
Insights zone 3 (I3)
Eilish Gilvarry
Methods and measurement of economic cost of substance use
16:50
to
18:20
Central square 3 (C3)
Rosalie Pacula
New methods
16:50
to
18:20
Central square 2 (C2)
André Noor
18:30
Lessons from the field
Measuring and monitoring drug policy for research, surveillance and practice
18:30
to
19:30
Networking zone 1 (N1)
Rosalie Pacula
Software-automated approach to monitoring online e-shops offering new psychoactive substances
18:30
to
19:30
Futures zone 3 (F3)
Vendula Belackova
Martin Pazitny
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
Nightlife, festivals and other recreational settings
18:30
to
19:30
Networking zone 3 (N3)
Andrew Bennet
Prevention science and measurement of demand reduction quality standards
18:30
to
19:30
Central square 1 (C1)
Nicola Singleton
Friday, 25 October
10:45
online registration required
Supporting future cannabis policy/achieving a Standard Joint Unit – FuturiZe workshop
10:45
to
12:15
Futures zone 3 (F3)
Antoni Gual
Hugo López-Pelayo
Drug policy debates: how are routine monitoring data used?
10:45
to
12:15
Insights zone 2 (I2)
Lies Gremeaux
Diversity in behavioural addictions
10:45
to
12:15
Networking zone 1 (N1)
Fernando Fernandez-Aranda
Therapeutic horizons II
10:45
to
12:15
Central square 1 (C1)
Felix Carvalho
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
10:55
Oral presentation
Dynamics in emerging drug use prevalence among people who inject drugs in Ukraine between 2013 and 2017
10:55
to
11:10
Central square 3 (C3)
Slava Kushakov
11:00
Short communication
Do more people in Europe need treatment for problems related to cocaine use? An analysis of cocaine treatment demand in nine European countries
11:00
to
11:10
Networking zone 4 (N4)
Antoine Jérôme
Oral presentation
Lessons learned from 25 years of drug checking in the Netherlands
11:00
to
11:15
Insights zone 4 (I4)
Laura Smit-Rigter
Oral presentation
Views about the disease and brain disease model of addiction: an international survey of addiction treatment providers in the USA, UK and Australia
11:00
to
11:15
Networking zone 1 (N1)
Anthony Barnett
11:10
Short communication
Psychostimulant induce neuronal plasticity by cytoskeleton remodeling via cdc42 pathway
11:10
to
11:20
Networking zone 4 (N4)
Andrea Lobo
Oral presentation
Patterns of NPS consumption and perceived risks and benefits: results of online survey in Georgia
11:10
to
11:25
Central square 3 (C3)
David Otiashvili
11:15
Oral presentation
Harm reduction agencies and monitoring the responses to drug-related harm
11:15
to
11:30
Insights zone 4 (I4)
Tuukka Tammi
Oral presentation
Reconsidering cannabis dependence
11:15
to
11:30
Networking zone 1 (N1)
Liz Temple
11:25
Oral presentation
Research on the use of new psychoactive substances and challenges in responding to it in Moldova (Eastern Europe)
11:25
to
11:40
Central square 3 (C3)
Eliza Kurcevic
11:30
Oral presentation
Monitoring drug use through wastewater analysis in Spain
11:30
to
11:45
Insights zone 4 (I4)
José Benito Quintana
Oral presentation
Agreement degree with the content of the Substance Addiction Consequences Scale items - The development of a new instrument.
11:30
to
11:45
Networking zone 1 (N1)
Paulo Seabra
11:40
Short communication
Crackland in Brazil: epidemiological monitoring method and results
11:40
to
11:50
Networking zone 4 (N4)
Clarice Madruga
Oral presentation
Drug use, HIV, HCV, including in prisons, in Eastern Europe: trends and implications for policy and programmes
11:40
to
11:55
Central square 3 (C3)
Lyuba Azbel
11:45
Oral presentation
ESCAPE (European Syringe Collection & Analysis Project Enterprise): a multi-city study of monitoring consumption trends of people who inject drugs
11:45
to
12:00
Insights zone 4 (I4)
Thomas Néfau
Oral presentation
Characterising people that demanded drug treatment in Catalonia: a cluster analysis
11:45
to
12:00
Networking zone 1 (N1)
Xavier Majó
11:50
Short communication
'I have no clue why I’m doing this' – a qualitative study on crack cocaine use in Frankfurt, Germany
11:50
to
12:00
Networking zone 4 (N4)
Bernd Werse
12:20
Poster
Illegal drug trends in Taiwan, 2009-2018
12:20
to
13:20
Guided poster tours room
Kai-Hsiang Kang
Poster
Gender convergence in alcohol consumption: outcomes from general population survey on drugs, Portugal 2001-2016/17
12:20
to
13:20
Guided poster tours room
Clara Vital
Poster
Monitoring recreational drug use in Switzerland
12:20
to
13:20
Guided poster tours room
Dominique Schori
Poster
Prevalence and patterns of drug use indicator (‘GPS’)
12:20
to
13:20
Guided poster tours room
Federica Mathis
Poster
European web survey on drugs: patterns of use
12:20
to
13:20
Guided poster tours room
João Matias
13:30
Oral presentation
The advantages and challenges of developing a national earlier warning system - Transforming Bergen Earlier Warning System (BEWS) into Norwegian National Earlier Warning System (NNEWS).
13:30
to
13:45
Insights zone 2 (I2)
Else Kristin Utne Berg
13:45
Oral presentation
New psychoactive substances in Portugal
13:45
to
14:00
Insights zone 2 (I2)
Ludmila Carapinha
14:00
Oral presentation
Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among high-risk drug users in Israel.
14:00
to
14:15
Insights zone 2 (I2)
Barak Shapira
14:15
Oral presentation
Use of physiologically based pharmacokinetic modelling of new psychoactive substances
14:15
to
14:30
Insights zone 2 (I2)
Nuno Elvas Silva
14:30
Oral presentation
Combining monitoring data to evaluate responses to NPS: the case of 4-FA in the Netherlands
14:30
to
14:45
Insights zone 2 (I2)
Margriet van Laar
16:50
Description of the contents of the workshop
16:50
to
17:00
Insights zone 1 (I1)
Eberhard Schatz
Oral presentation
Prevalence and patterns of NPS use in general and school European populations
16:50
to
18:20
Central square 3 (C3)
Julian Vicente
Oral presentation
NPS use in self-selected respondents of the population (EU web-survey)
16:50
to
18:20
Central square 3 (C3)
Julian Vicente
Oral presentation
Assessing patterns of use of new psychoactive substances (NPS) – the NPS Euronet project
16:50
to
18:20
Central square 3 (C3)
Noelia Salgueiro-González
Oral presentation
Drug trends at UK festivals and self-reported information and treatment needs by people who use NPS
16:50
to
18:20
Central square 3 (C3)
Katy MacLeod
Oral presentation
New psychoactive substance use among marginalised and high risk populations in Europe
16:50
to
18:20
Central square 3 (C3)
Jane Mounteney
17:00
Oral presentation
Introduction and short presentation on harm reduction monitoring
17:00
to
17:15
Insights zone 1 (I1)
Dagmar Hedrich
17:15
Oral presentation
Introduction of methods developed for CSO monitoring
17:15
to
17:30
Insights zone 1 (I1)
Tuukka Tammi
17:30
Oral presentation
Focus on monitoring HCV, overdose prevention and new drug trends
17:30
to
17:45
Insights zone 1 (I1)
Daan van der Gouwe
18:30
Oral presentation
USODROGAS.PT: Portugal's drug use: a web based survey
18:30
to
18:45
Central square 1 (C1)
André Tadeu
18:45
Oral presentation
Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
18:45
to
19:00
Central square 1 (C1)
Henning Pettersen
19:00
Oral presentation
Validation of the Routine Opioid Outcome Monitoring (ROOM) screening tool in patients prescribed opioids for chronic pain
19:00
to
19:15
Central square 1 (C1)
Suzanne Nielsen
19:15
Oral presentation
Adoption of publication procedures to improve research integrity by alcohol and other drug journals
19:15
to
19:30
Central square 1 (C1)
Dennis Gorman
Thursday, 24 October
11:00
Short communication
Quantitative and qualitative evidences for better gender-based prevention of adolescent addictive behaviours, with and without substance
11:00
to
11:10
Networking zone 4 (N4)
Patricia Gómez
Short communication
Neuropsychological functioning, psychopathology, and parenting behaviours in the context of substance use disorders: which are the implications for treatment?
11:00
to
11:10
Networking zone 3 (N3)
Alessio Porreca
Oral presentation
Prevalence of injecting and non-injecting high-risk opioid use in Switzerland over more than two decades: understanding associations with opioid agonist treatment and needle and syringe programs
11:00
to
11:15
Insights zone 1 (I1)
Carlos Nordt
11:10
Short communication
The European Web Survey on Drugs: patterns of use of new psychoactive substances in Belgium
11:10
to
11:20
Networking zone 4 (N4)
Lies Gremeaux
Short communication
Childhood adversity within adolescent friendship groups: Implications for subsequent substance use disorders
11:10
to
11:20
Networking zone 3 (N3)
Lauren Bishop
11:15
Oral presentation
20 years of communication on drugs: What are the new challenges for a monitoring centre?
11:15
to
11:30
Insights zone 1 (I1)
Julie-Emilie Ades
11:20
Short communication
From chronology to processes: combining biographical interview with episodic analysis in a life story
11:20
to
11:30
Networking zone 4 (N4)
Isabel María Herrera-Sánchez
Short communication
Cause-specific hospitalisation and death in a cohort of people who use heroin and crack cocaine in London, England: the importance of non-communicable diseases, skin infections, head injuries and dental caries
11:20
to
11:40
Networking zone 3 (N3)
Dan Lewer
11:30
Short communication
Coding multiple drug use in ICD-10 and ICD-11
11:30
to
11:40
Networking zone 4 (N4)
Espen Walderhaug
Short communication
Yearning to be better than good –Lithuanian students of medicine use of cognitive enhancers among
11:30
to
11:40
Networking zone 3 (N3)
Aiste Lengvenyte
Oral presentation
Monitoring local drug trends – looking back at 17 years of 'Monitoring system drug trends' in Frankfurt, Germany
11:30
to
11:45
Insights zone 1 (I1)
Bernd Werse
11:40
Short communication
The scientific portrayal of decriminalisation models for psychoactive substances: a scoping review
11:40
to
11:50
Networking zone 4 (N4)
Isabel María Herrera-Sánchez
Short communication
New issues regarding drug-related deaths: combined suicide
11:40
to
11:50
Networking zone 3 (N3)
Mateja Jandl
Short communication
The scientific portrayal of decriminalisation models for psychoactive substances: a scoping review
11:40
to
11:50
Networking zone 4 (N4)
Daniela Filipa Ferreira
11:45
Oral presentation
Implementing treatment demand indicator in West Africa: challenges and lessons learnt
11:45
to
12:00
Insights zone 1 (I1)
Dominique Lopez
11:50
Short communication
The role of the juveniles in the structure and dynamics of the illegal drug market in the Republic of Croatia
11:50
to
12:00
Networking zone 4 (N4)
Short communication
Women and HIV in prison setting: data from the Italian ROSE network
11:50
to
12:00
Networking zone 3 (N3)
12:00
Short communication
Non-national clients in Belgian drug treatment: different profile characteristics compared to Belgian clients
12:00
to
12:10
Networking zone 3 (N3)
Charlotte De Kock
Short communication
Lifetime prevalence of drug use before imprisonment in Europe: results from a systematic literature review
12:00
to
12:10
Networking zone 4 (N4)
Oral presentation
An Australian clinical research priority setting study for substance use disorder due to methamphetamine and emerging drugs of concern
12:00
to
12:15
Insights zone 1 (I1)
Krista J. Siefried
12:10
Short communication
Public participation in effective development of a regional drug strategy: experiences from the South East region of Ireland
12:10
to
12:20
Networking zone 4 (N4)
Michelle Foley
12:20
Poster
Epidemiology of illicit drug use and policy evaluation: the heroin epidemics example
12:20
to
13:20
Guided poster tours room
Carla Rossi
Poster
Scalable family therapy training materials for adolescents with substance use disorder (UNFT)
12:20
to
13:20
Guided poster tours room
Anja Busse
Poster
Community Reinforcement and Family Training (CRAFT) - a cluster randomised controlled trial comparing individual, group and self-help interventions.
12:20
to
13:20
Guided poster tours room
Randi Bilberg
Poster
Can environmental prevention effectively complement efforts in responding to the psychoactive substance abuse among forensic patients?
12:20
to
13:20
Guided poster tours room
Poster
Development of the UNODC-WHO quality assurance mechanism and standards for the treatment of drug use disorders
12:20
to
13:20
Guided poster tours room
Annette Dale-Perera
Anja Busse
Poster
Preliminary methodological analysis on the lexicometric assessment of laws and drugs policies and evaluation of social outcomes
12:20
to
13:20
Guided poster tours room
Carla Rossi
Poster
Development of the UNODC-WHO quality assurance mechanism and standards for the treatment of drug use disorders
12:20
to
13:20
Guided poster tours room
Wataru Kashino
13:20
Oral presentation
Review of evidence on the prevalence of current use of cognitive enhancers, the effects of their use on workers and on work, as well as an introduction to the implications for occupational safety and health (OSH)
13:20
to
14:50
Futures zone 2 (F2)
Karen Dale
Oral presentation
The need for further evidence to support policy making and practical interventions
13:20
to
14:50
Futures zone 2 (F2)
William Cockburn
Annick Starren
Oral presentation
Challenges posed from a policy perspective and look into current strategies for reduction of work-related injuries and ill-health, caused by drug use at the workplace
13:20
to
14:50
Futures zone 2 (F2)
Marie-Claire Lambrechts
Poster
Trends on the Dutch drug market identified by DIMS in 2018
13:20
to
14:50
Guided poster tours room
Laura Smit-Rigter
Poster
Gendered sources of drug supply for recreational drug users in the European Web Survey on Drugs
13:20
to
14:50
Guided poster tours room
Michael Vuolo
Poster
Trends in primary substance mentioned by patients entering treatment for illicit substance use in Belgium between 2012 and 2018
13:20
to
14:50
Guided poster tours room
Antoine Jérôme
Poster
Criminal reactions and reduction of crime and drug use in drug-using offenders
13:20
to
14:50
Guided poster tours room
Olga Souza Cruz
Poster
Fatal traffic accidents in connection to driving under the influence of psychoactive substances
13:20
to
14:50
Guided poster tours room
Ada Hocevar Grom
Poster
HIV infection in drug users in harm reduction structures
13:20
to
14:50
Guided poster tours room
Isabel Ponte
Poster
Drug-related deaths and mortality in Europe
13:20
to
14:50
Guided poster tours room
Federica Mathis
Poster
Demand for drug treatment in Europe: the Treatment Demand indicator (TDI)
13:20
to
14:50
Guided poster tours room
Linda Montanari
Poster
Non-medical prescription drug use among Estonian adults
13:20
to
14:50
Guided poster tours room
Sigrid Vorobjov
Poster
Monitoring drug-related infectious diseases in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
Poster
Estimating the number of people who inject drugs (PWID) in Europe
13:20
to
14:50
Guided poster tours room
Thomas Seyler
13:25
Oral presentation
The use of performance enhancing drugs managed in the workplace
13:25
to
14:50
Futures zone 2 (F2)
Natalie Lotzman
13:30
Oral presentation
'A more accurate understanding of drug use': a critical analysis of wastewater analysis technology for drug policy
13:30
to
13:45
Networking zone 1 (N1)
Kari Lancaster
Oral presentation
Use of contingency management (positive reinforcement with financial incentives) to encourage abstinence from heroin (PRAISE): a UK cluster randomised trial
13:30
to
13:45
Insights zone 4 (I4)
Nicola Metrebian
Timothy Weaver
Oral presentation
Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England
13:30
to
13:45
Central square 2 (C2)
John Marsden
Oral presentation
Understanding opioid drugs and important drug interactions in opioid-related deaths
13:30
to
13:45
Central square 1 (C1)
Graeme Henderson
13:45
Oral presentation
Beyond the substances: a multi-criteria analysis of spread of drugs in Europe
13:45
to
14:00
Networking zone 1 (N1)
Giuliano Resce
Oral presentation
Opioid maintenance treatment (OMT) – not life-long for all women? 10 years follow-up after pregnancy - how many stop OMT and what are the results?
13:45
to
14:00
Insights zone 4 (I4)
Gabrielle Welle-Strand
Oral presentation
Results of mortality cohort study of problem drug users in Poland.
13:45
to
14:00
Central square 2 (C2)
Janusz Sieroslawski
Oral presentation
Fentanyl overdose: naloxone reversibility and reduced cross tolerance
13:45
to
14:00
Central square 1 (C1)
Rob Hill
14:00
Oral presentation
A smartphone app to assess alcohol consumption behaviours: development, validity, compliance and reactivity
14:00
to
14:15
Networking zone 1 (N1)
Rob Hester
Oral presentation
A look at the dark side of addiction treatment: a profile of those who drop out
14:00
to
14:15
Insights zone 4 (I4)
João Augusto
Oral presentation
Heroin overdose: experimental testing and measurement in the laboratory (preliminary findings)
14:00
to
14:15
Central square 1 (C1)
Basak Tas
Oral presentation
Nasal naloxone for overdose prevention in Norway: results from the first four years
14:00
to
14:15
Central square 2 (C2)
Oral presentation
Nasal naloxone for overdose prevention in Norway: results from the first four years
14:00
to
14:15
Central square 2 (C2)
Desiree Eide
14:15
Oral presentation
New and fully automated workflow for alcohol consumption and drugs of abuse monitoring from one single blood droplet
14:15
to
14:30
Networking zone 1 (N1)
Marc Luginbühl
Oral presentation
Methadone serum concentrations and influencing factors: a naturalistic observational study
14:15
to
14:30
Insights zone 4 (I4)
Fatemeh Chalabianloo
Oral presentation
Incidence and predictors of drug overdoses among a cohort of patients treated for substance use disorder
14:15
to
14:30
Central square 2 (C2)
Birgitte Thylstrup
Oral presentation
Chronic obstructive pulmonary disease (COPD) among opioid dependent patients in substitution treatment. A diagnostic study
14:15
to
14:30
Central square 1 (C1)
Philip Bruggmann
14:30
Oral presentation
Is methadone treatment more effective for lower socio-economic status opiate users? Results from a case crossover study in Lazio
14:30
to
14:45
Insights zone 4 (I4)
Antonella Camposeragna
Oral presentation
MDMA-related deaths in Australia
14:30
to
14:45
Central square 2 (C2)
Amanda Roxburgh
Oral presentation
Analysis of the content of used injecting paraphernalia in the Sydney supervised injecting facility
14:30
to
14:45
Central square 1 (C1)
Elodie Lefrançois
15:00
Poster
Dosing of naloxone in opioid overdose outside of hospital. Observational data 2014 -18 in Oslo, Norway
15:00
to
16:30
Guided poster tours room
Ida Tylleskär
Poster
Increasing trend and differential patterns of opioids prescribing by patient characteristics in primary care in Belgium: a registry-based study
15:00
to
16:30
Guided poster tours room
Catharina Matheï
Poster
Patterns in analgesic opioids use in Germany and France: improved pain management and risks of misuse
15:00
to
16:30
Guided poster tours room
Jessica Neicun
Poster
Barriers to establishing take-home naloxone programmes
15:00
to
16:30
Guided poster tours room
Sibella Hare Breidahl
Poster
Patient characteristics and expected needs: an opioid substitution programme findings
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Benzodiazepine use among patients in opioid substituttion treatment: a cross sectional study
15:00
to
16:30
Guided poster tours room
Catarina Oliveira
Poster
Hospitalisation of children after prenatal exposure to Methadone and Buprenorphine: national registry study from Czechia
15:00
to
16:30
Guided poster tours room
Blanka Nechanská
Poster
Uncovering trajectories of satisfaction with injectable opioid agonist treatment for severe opioid use disorder
15:00
to
16:30
Guided poster tours room
Kirsten Marchand
Poster
Predicting pain intensity following discontinuation of long-term opioid therapy among patients with and without substance use disorders
15:00
to
16:30
Guided poster tours room
Crystal Smith
Poster
Addressing the opioid crisis: engagement in multidisciplinary care
15:00
to
16:30
Guided poster tours room
Tianna Magel
Poster
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018
15:00
to
16:30
Guided poster tours room
Tina Lam
15:10
Oral presentation
‘EMSS Nightlife survey’: design and snapshot of findings in 5 European countries
15:10
to
15:25
Networking zone 1 (N1)
Meryem Grabski
Oral presentation
Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands
15:10
to
15:25
Insights zone 4 (I4)
Daan van der Gouwe
15:25
Oral presentation
Methodological challenges: comparing different samples and sampling strategies
15:25
to
15:40
Networking zone 1 (N1)
Jon Waldron
15:40
Oral presentation
Ecological momentary assessment of substance use (consequences) among ecstasy users
15:40
to
15:55
Networking zone 1 (N1)
Ruben van Beek
Oral presentation
A descriptive analysis of the illicit supply of new psychoactive substances within and from China
15:40
to
15:55
Insights zone 4 (I4)
Minqi Zhao
15:55
Oral presentation
Contextual analysis and comparison of nightlife cultures in five European countries
15:55
to
16:10
Networking zone 1 (N1)
Tina Van Havere
Oral presentation
MDMA dosage in XTC tablets: size matters
15:55
to
16:10
Insights zone 4 (I4)
Ruben Vrolijk
16:10
Oral presentation
Insight into the reliability of self-report of substance use in nightlife populations: a breath sampling study
16:10
to
16:25
Networking zone 1 (N1)
Kristin Feltmann
Oral presentation
Understanding drug markets: results of the MARSTUP study
16:10
to
16:25
Insights zone 4 (I4)
Frank Zobel
16:50
Oral presentation
Modeling economical costs of alcohol consumption in Germany: the GECO-ALC1 project
16:50
to
17:05
Central square 3 (C3)
Jakob Manthey
17:00
Oral presentation
Interpreting wastewater data alongside other population-level indicators of stimulant use
17:00
to
17:15
Central square 2 (C2)
Hayley Jones
Oral presentation
Informal social support as a crucial factor in recovery from drug misuse
17:00
to
17:15
Insights zone 3 (I3)
Filipa Gonçalves
Oral presentation
Framing the non-medical use of tramadol in Africa- global opioid crises, medicrime or inadequate healthcare systems
17:00
to
17:20
Insights zone 2 (I2)
Axel Klein
17:05
Oral presentation
Estimating substance use costs and harms in Canada
17:05
to
17:20
Central square 3 (C3)
Matthew Young
17:15
Oral presentation
What are the indirect causes of death among people who use drugs in Ireland? Findings from a comprehensive special register on drug related deaths
17:15
to
17:30
Central square 2 (C2)
Suzi Lyons
Oral presentation
Social and professional integration, addictive behaviours and time perspectives: personal experiences of young adults involved in a low-threshold employment program in Montreal
17:15
to
17:30
Insights zone 3 (I3)
Vincent Wagner
17:20
Oral presentation
Captagon: knowns and unknows
17:20
to
17:35
Insights zone 2 (I2)
Laurent Laniel
Oral presentation
Morbi-mortality consequences of misuse of psychoactive prescription drugs in Portugal: a retrospective observational study - the MisuMedPT project
17:20
to
17:35
Central square 3 (C3)
Ana Araújo
17:30
Oral presentation
Temporary and constant remission: a record-linkage study of a national cohort of people with psychoactive drug use disorders
17:30
to
17:45
Central square 2 (C2)
Morten Hesse
Oral presentation
General practice patients in treatment for substance use problems at different levels of care: an observational study using two data sources
17:30
to
17:45
Insights zone 3 (I3)
Nicole Boffin
17:35
Oral presentation
Libya’s changing drug trafficking dynamics on the coastal and desert borders
17:35
to
17:50
Insights zone 2 (I2)
Mark Micallef
17:45
Oral presentation
Effective policies to support autonomous attempts to quit opioid use - a cross-sectional study across 14 countries
17:45
to
18:00
Central square 2 (C2)
Larissa Maier
Oral presentation
The Healthy Addiction Treatment (HAT) recovery model for addiction nursing services
17:45
to
18:00
Insights zone 3 (I3)
Catherine Comiskey
17:50
Oral presentation
Harm reduction services in MENA region: Assessment of the situation and response by MENAHRA
17:50
to
18:05
Insights zone 2 (I2)
Elie Aaraj
18:00
Oral presentation
'Once a drug addict, always a drug addict': the role of stigma in recovery
18:00
to
18:15
Insights zone 3 (I3)
Joana Fonseca
18:05
Oral presentation
Wastewater-based drug epidemiology data in selected community compared to a forensic toxicology investigation finding. Sewage sensors towards evaluation of drug use trends
18:05
to
18:20
Insights zone 2 (I2)
Bilel Moslah
18:30
Oral presentation
Babel and Bleak House; what ELDD can and can’t tell us about drug laws in 30 countries
18:30
to
19:30
Networking zone 1 (N1)
Brendan Hughes
Oral presentation
tba
18:30
to
19:30
Networking zone 1 (N1)
Scott Burris
18:40
Short communication
Opioid-related problems in Baltic States and Poland: has the turning point come?
18:40
to
18:50
Networking zone 4 (N4)
Katri Abel-Ollo
Short communication
Recommendations for NPS-targeted initiatives in Belgium
18:40
to
18:50
Networking zone 3 (N3)
Anton van Dijck
Oral presentation
Use of an adapted version of the community readiness assessment to examine the current state of alcohol prevention in communities in Spain and Portugal
18:40
to
18:55
Central square 1 (C1)
Claudia Pischke
18:50
Short communication
Estonia’s fentanyl battle: time to scale-up overdose prevention strategy?
18:50
to
19:00
Networking zone 4 (N4)
Sibella Hare Breidahl
Short communication
Predicting the onset of ketamine use among frequent nightlife attendees
18:50
to
19:00
Networking zone 3 (N3)
Charlotte van Miltenburg
18:55
Oral presentation
Building systems to promote prevention science: challenges and strategies
18:55
to
19:10
Central square 1 (C1)
Peer van der Kreeft
19:00
Short communication
Assessment of possibilities for raising the quality of health care provided to opioid users by increasing access to substitution treatment
19:00
to
19:10
Networking zone 4 (N4)
Boguslawa Bukowska
Short communication
Why a zero tolerance drug policy for festivals is not working (well)
19:00
to
19:10
Networking zone 3 (N3)
Jochen Schrooten
19:10
Short communication
Rising incidence of ageing opioid users within the EU wide treatment
19:10
to
19:20
Networking zone 4 (N4)
Anne Marie Carew
Short communication
Towards gender-sensitive responses in the drugs field: Intersections between sexual violence, drug use in nightlife environments
19:10
to
19:20
Networking zone 3 (N3)
Cristiana Vale Pires
Oral presentation
Minimum quality standards in drug demand reduction - from policy consensus to assessment and implementation
19:10
to
19:25
Central square 1 (C1)
Matej Košir
19:20
Short communication
Setting up a HPLC in a 7-day psychedelic music festival: drug checking moving forward
19:20
to
19:30
Networking zone 3 (N3)
Daniel Martins
Short communication
The neglected public health problem of opioid use among offenders - why we have failed and where we can improve.
19:20
to
19:30
Networking zone 4 (N4)
Friday, 25 October
10:45
Oral presentation
Food addiction and impaired executive functions in women with obesity
10:45
to
12:15
Networking zone 1 (N1)
Fernando Fernandez-Aranda
Oral presentation
Neural correlates of cue-reactivity and craving in individuals with buying-shopping disorder.
10:45
to
12:15
Networking zone 1 (N1)
Patrick Trotzke
Oral presentation
Are the practices of 'free-to-play' and 'pay-to-win' games new risk behaviours?
10:45
to
12:15
Networking zone 1 (N1)
Jean-Michel Costes
Oral presentation
‘Hooked on the mirror’: the emergence of a new cohort of gym users affected by exercise addiction, appearance anxiety and the use of fitness supplements
10:45
to
12:15
Networking zone 1 (N1)
Ornella Corazza
Oral presentation
The importance of a therapeutic contract in a CBT gambling disorder treatment
10:45
to
12:15
Networking zone 1 (N1)
Bruno Ricardo Neto Teixeira Bento
Supporting future cannabis policy/achieving a Standard Joint Unit – FuturiZe workshop
10:45
to
12:15
Futures zone 3 (F3)
Hugo López-Pelayo
Supporting future cannabis policy/achieving a Standard Joint Unit backcasting workshop workshop
10:45
to
12:15
Futures zone 3 (F3)
Antoni Gual
10:50
Oral presentation
Reitox: the European information network on drugs and drug addiction
10:50
to
11:00
Insights zone 2 (I2)
Sandrine Sleiman
10:55
Oral presentation
Memory-focused cognitive therapy for cocaine use disorder: theory, procedures and preliminary evidence from an external pilot randomised controlled trial
10:55
to
11:10
Central square 1 (C1)
John Marsden
11:00
Oral presentation
Case study from Ireland: Use of data in public debate on alternative approaches to the possession of drugs for person use
11:00
to
11:15
Insights zone 2 (I2)
Brian Galvin
11:10
Oral presentation
Treatment of youth with substance use disorder and co-existing mental disorder: the MOVE programme.
11:10
to
11:25
Central square 1 (C1)
Mads Uffe Pedersen
11:15
Oral presentation
Case study from Czech Republic: role of evidence in drug (de)criminalisation in the Czech Republic
11:15
to
11:30
Insights zone 2 (I2)
Viktor Mravčík
11:25
Oral presentation
The impact of maternal alexithymia on parenting behaviours in the context of substance use disorders
11:25
to
11:40
Central square 1 (C1)
Alessio Porreca
11:30
Oral presentation
Case study from France: Use of data in public debate on alternative approaches to the possession of drugs for person use
11:30
to
11:45
Insights zone 2 (I2)
Ivana Obradovic
11:40
Oral presentation
The role of social environment in pathways to recovery: a scoping review
11:40
to
11:55
Central square 1 (C1)
João Pedro Ramos
11:45
Oral presentation
Decision-making and the use of evidence
11:45
to
12:05
Insights zone 2 (I2)
Alison Ritter